Skip To Main Content
Neta Barashi on Muck Rack

Neta Barashi

As seen in: Annals of the Rheumatic Diseases, The Journal of Clinical Investigation, JHEP Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neta

Contact Neta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis

|
By JCI Insight, Michal Segal-Salto, Neta Barashi, Raanan Greenman
| The Journal of Clinical Investigation
Abstract ˆCCL24 is a pro-fibrotic, pro-inflammatory chemokine expressed in several chronic fibrotic diseases. In the liver, CCL24 plays a role in fibrosis and inflammation, and blocking CCL24 led to reduced liver injury in experimental models. We studied the role of CCL24 in primary sclerosing cholangitis (PSC) and evaluated the potential therapeutic effect of blocking CCL24 in this disease.
Open in Who Shared Issue with article?

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage

|
By Michal Segal-Salto, Chemom Ab, Neta Barashi
| JHEP Reports Verified
Highlights • CCL24 is a chemokine that regulates inflammatory and fibrotic activities through its receptor, CCR3. • Significant expression of CCL24 and CCR3 were found in liver biopsies and blood samples from patients with NAFLD/NASH. • CM-101, a monoclonal antibody that selectively targets CCL24, significantly attenuates fibrotic and inflammatory processes. • Blocking CCL24 may have a potential therapeutic effect in NASH and liver fibrosis.
Open in Who Shared Issue with article?

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

|
By Adi Mor, Michal Segal Salto, Avi Katav, Neta Barashi
| Annals of the Rheumatic Diseases Verified
Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis Adi Mor1, Michal Segal Salto1, Avi Katav1, Neta Barashi1, Victoria Edelshtein1, Mirko Manetti2, Yair Levi3, Jacob George4, Marco Matucci-Cerinic5 1 R&D, ChemomAb Ltd, Tel Aviv, Israel 2 Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy 3 Department of Internal Medicine E, Meir Medical Center, Kfar-Saba, Israel 4 Heart...
Open in Who Shared Issue with article?
See all 4 articles